Novo Nordisk (0QIU) Gets a Buy from UBS
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Tourmaline Bio price target raised to $43 from $42 at Wedbush
Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...
Drugmakers Agree to Participate in Second Round of Price Negotiations
The second cycle of negotiations will take place under President Donald Trump's administration. The U.S. government has said ...
Council on Foreign Relations11h
American Pharmaceutical Companies Still Aren’t Paying Tax in the U.S.
K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.
Litigation Trends to Watch: COVID-19 Anniversary, Warranty Expiration Dates and Misuses of 401(k) Funds Trigger Lawsuits
Law.com Radar detected an uptick in securities cases centering on the COVID-19 pandemic. Eight federal lawsuits were surfaced ...
Investopedia21h
Corporate Business Travel: Everything You Need to Know
Elysse Bell is a finance and business writer for Investopedia. She writes about small business, personal finance, technology, and more. Katie Miller is a consumer financial services expert.